Results 71 to 80 of about 527 (122)

Myofilament-level effects of aficamten increase diastolic chamber volumes and maintain cardiac output through preserved length-dependent force generation in healthy rat and canine myocardium. [PDF]

Basic Res Cardiol
Sárkány F, Priksz D, Juhász B, Fazekas LÁ, Németh N, Szentandrássy N, Horváth B, Kovács ZM, Borbély A, Ráduly AP, Tóth A, Fagyas M, Bódi B, Papp Z.   +13 more
europepmc   +1 more source

Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. [PDF]

Eur Heart J
Tower-Rader A, Masri A, Nassif ME, Abraham TP, Barriales-Villa R, Choudhury L, Cooper RM, Elliott PM, Maron MS, Olivotto I, Oreziak A, Owens AT, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Liu X, Malik FI, Melloni C, Simkins TJ, Wei J, Saberi S.   +21 more
europepmc   +1 more source

Structure-Function Relationship as the Foundation for Cardiac Myosin Inhibition in Hypertrophic Cardiomyopathy. [PDF]

Circulation
Kawana M, Ruppel KM, Spudich JA.
europepmc   +1 more source

The ODYSSEY-HCM and MAPLE-HCM studies: the role of cardiac myosin inhibitors in hypertrophic cardiomyopathy (obstructive and non-obstructive). [PDF]

Eur Heart J Suppl
Biagini E, Schiavo MA.
europepmc   +1 more source

Correction: Amr et al. Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort. Reviews in Cardiovascular Medicine. 2024; 25(6): 225. [PDF]

Rev Cardiovasc Med
Amr A, Kayvanpour E, Reich C, Koelemen J, Asokan S, Frey N, Meder B, Sedaghat-Hamedani F.   +7 more
europepmc   +1 more source

Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. [PDF]

Heart Fail Rev
Grupper A, Sverdlov AL, Cheema BS, Nasrollahizadeh A, Hosseini K.   +4 more
europepmc   +1 more source

Efficacy and Safety of Mavacamten and Aficamten in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. [PDF]

Crit Pathw Cardiol
Ibrahim M, Kashif A, Arfin SMW, Mubeen M, Zafar A, Balach R, Ahmed A, Musani MH, Greene SJ, Fonarow GC, Sohail MU.   +10 more
europepmc   +1 more source

Therapeutic Sequencing in Obstructive Hypertrophic Cardiomyopathy: Seeing the Forest Through the Trees. [PDF]

JACC Heart Fail
Reza N.
europepmc   +1 more source

Bibliometric and visualized analysis of research trends and knowledge structure in novel pharmacological treatments for hypertrophic cardiomyopathy. [PDF]

J Cardiothorac Surg
Chen Z, Ai F, Li J, Cheng B, Cheng W, Li Y.   +5 more
europepmc   +1 more source

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.

JAMA Cardiol
Lewis GD, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, de Barros Correia E, Dybro AM, Kulac IJ, Lakdawala NK, Mann A, Maron MS, McGinnis S, Nair A, Newlands C, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Elliott PM, MAPLE-HCM Investigators.   +34 more
europepmc   +1 more source